Nichi-Iko to buy Sagent in US$736mil cash deal


TORONTO: Nichi-Iko Pharmaceutical Co agreed to buy Sagent Pharmaceuticals Inc for US$736mil in cash, allowing the Japanese company to build its presence in the US market as it looks to become one of the world's top manufacturers of generic medicines.

Nichi-Ikowill pay US$21.75 per share, a premium of about 40% to Sagent's July 8 closing price, the companies said in a statement yesterday.

Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Business , Nichi-Iko , Sagent , buy , generic , US market

   

Next In Business News

AI boom set to fuel data centre deals in Asia
TotalEnergies mulls moving listing to Wall St
Rig dearth aggravates Indonesia’s declining oil and gas production
Optimistic growth prospects for Focus Point Holdings
Epsom sees more student enrolment from UK
SC: Planners should give sound financial advice
Japan’s helping hand in BoE June rate cut window
Carsome turns Ebitda positive in 1Q24 on business scale
Cocoa-free chocolate maker raises US$52mil
Go Hub gets nod to list on ACE Market

Others Also Read